Seeing Is Believing
Currently out of the existing stock ratings of Elmar Kraus, 14 are a BUY (63.64%), 8 are a HOLD (36.36%).
Analyst Elmar Kraus, currently employed at STIFEL, carries an average stock price target met ratio of 68.75% that have a potential upside of 14.19% achieved within 181 days.
Elmar Kraus’s has documented 44 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 01-May-2024.
Analyst best performing recommendations are on ABBV (ABBVIE).
The best stock recommendation documented was for LLY (ELI LILLY AND COMPANY) at 1/21/2022. The price target of $291 was fulfilled within 75 days with a profit of $55.48 (23.56%) receiving and performance score of 3.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$213
$88.01 (70.41%)
$213
26 days ago
(27-Jun-2025)
39/68 (57.35%)
$86.92 (68.94%)
121
Buy
$187
$62.01 (49.61%)
$187
27 days ago
(26-Jun-2025)
9/22 (40.91%)
$60.08 (47.34%)
260
Hold
1 months 11 days ago
(12-Jun-2025)
7/32 (21.88%)
$112.06 (70.95%)
255
Hold
$121
$-3.99 (-3.19%)
$205
1 months 11 days ago
(12-Jun-2025)
25/28 (89.29%)
$-11.31 (-8.55%)
195
Buy
$169
$44.01 (35.21%)
$207
2 months 16 days ago
(07-May-2025)
23/35 (65.71%)
$51.79 (44.19%)
130
What Year was the first public recommendation made by Elmar Kraus?